Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Percutaneous Coronary Revascularization Clear all
Terminated Phase 3 Interventional

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

NCT03630055
View directory record Official record
Conditions
Radial Artery Occlusion
Interventions
Rivaroxaban 15 MG Oral Tablet [Xarelto]
Drug
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 22, 2026, 4:37 AM EDT
Completed No phase listed Observational Results available

Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions

NCT01917682
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases
Interventions
CorPath-assisted Percutaneous Coronary Intervention
Procedure
Lead sponsor
Siemens Healthineers Endovascular Robotics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
San Diego, California • Glenwood Springs, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Jul 22, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack

NCT01539590
View directory record Official record
Conditions
Myocardial Infarction
Interventions
BB3, Normal saline
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
21 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Minneapolis, Minnesota • New Haven, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Jul 22, 2026, 4:37 AM EDT
Not listed No phase listed Observational

Pro-calcitonin Marker as Indicator of Ischemia in Patients With Complicated Coronary Intervention.

NCT01609569
View directory record Official record
Conditions
Coronary Disease
Interventions
Not listed
Lead sponsor
Saint Michael's Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Jul 22, 2026, 4:37 AM EDT
Completed Not applicable Interventional

Shockwave Lithoplasty Compared to Cutting Balloon Treatment in Calcified Coronary Disease - A Randomized Controlled Trial

NCT06089135
View directory record Official record
Conditions
Treatment in Calcified Coronary Disease
Interventions
Intravascular Lithotripsy, Cutting Balloon
Device
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
21 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 22, 2026, 4:37 AM EDT
Completed No phase listed Observational Results available

Intracardiac T-wave Alternans and Ischemia

NCT00669552
View directory record Official record
Conditions
Ischemia
Interventions
Percutaneous coronary intervention
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Jul 22, 2026, 4:37 AM EDT
Completed No phase listed Observational

Xience V at Wake Forest University Baptist Medical Center (WFUBMC)

NCT00937573
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Stents
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 22, 2026, 4:37 AM EDT
Completed No phase listed Observational

In-hospital and Long-term Outcomes for Percutaneous Chronic Total Coronary Occlusion Revascularization in a High-volume, Multi-operator Program

NCT01946724
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Not listed
Lead sponsor
Piedmont Healthcare
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Jul 22, 2026, 4:37 AM EDT
Suspended Phase 4 Interventional Accepts healthy volunteers

Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury

NCT05435235
View directory record Official record
Conditions
Acute Kidney Injury, Percutaneous Coronary Intervention
Interventions
Dapagliflozin 10mg Tab
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jul 22, 2026, 4:37 AM EDT
Completed Phase 4 Interventional

Study of Unprotected Left Main Stenting Versus Bypass Surgery (LE MANS Study)

NCT00375063
View directory record Official record
Conditions
Coronary Artery Stenosis, Myocardial Revascularization, Myocardial Ischemia
Interventions
Percutaneous Coronary Intervention, Coronary Artery Bypass Grafting
Procedure
Lead sponsor
Ministry of Science and Higher Education, Poland
Government
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Bryn Mawr, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Jul 22, 2026, 4:37 AM EDT
Completed Not applicable Interventional

Enhancing Cardiac Rehabilitation Through Behavioral Nudges

NCT03834155
View directory record Official record
Conditions
Acute Myocardial Infarction, Percutaneous Coronary Intervention, Coronary Artery Disease, Valvular Disease, Chronic Stable Angina, Chronic Stable Heart Failure
Interventions
Hospital-based CR + Movn Application, Choice of Hospital or home-based CR + Movn Application, Hospital-based CR + Movn Application + Nudge, Choice of Hospital or home-based CR + Movn Application + Nudge
Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 100 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Jul 22, 2026, 4:37 AM EDT
Terminated Phase 3 Interventional Results available

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

NCT00305162
View directory record Official record
Conditions
Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
Interventions
Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor), Placebo bolus & placebo infusion, Placebo capsules - end of infusion, Placebo capsules - as soon as possible after randomization
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
8,882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Jul 22, 2026, 4:37 AM EDT
Withdrawn No phase listed Observational

Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?

NCT01991366
View directory record Official record
Conditions
ST-elevation Myocardial Infarction, Acute Myocardial Infarction
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Jul 22, 2026, 4:37 AM EDT
Completed No phase listed Observational

Emergency Medical Services (EMS) Telehealth to Speed STEMI Reperfusion

NCT06945900
View directory record Official record
Conditions
STEMI - ST Elevation Myocardial Infarction
Interventions
Telehealth
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
30 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 22, 2026, 4:37 AM EDT
Completed No phase listed Observational Results available

FUnctional diagnoSIs of corONary Stenosis (FUSION)

NCT04356027
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Stenosis
Interventions
ICA (Invasive Coronary Angiography), OCT, FFR, VFR Analysis
Procedure · Other
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
28
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jul 22, 2026, 4:37 AM EDT
Recruiting Not applicable Interventional

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

NCT04634240
View directory record Official record
Conditions
Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
University of British Columbia
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
55
States / cities
Huntsville, Alabama • Phoenix, Arizona • Palo Alto, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jul 22, 2026, 4:37 AM EDT
Completed Phase 3 Interventional

Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI

NCT00093184
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Angiomax (bivalirudin) anticoagulant
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Blue Island, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2006 · Synced Jul 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

Safety Evaluation of Intracoronary Infusion of Extracellular Vesicles in Patients Following Coronary Stent Implantation

NCT04327635
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
PEP
Drug
Lead sponsor
Christopher J. McLeod
Other
Eligibility
21 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 22, 2026, 4:37 AM EDT
Completed No phase listed Observational

Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

NCT01582217
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Dual Antiplatelet Therapy, Aspirin, Clopidogrel
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Jul 22, 2026, 4:37 AM EDT
Completed Phase 4 Interventional Results available

EVOLVE Short DAPT Study

NCT02605447
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
89
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Jul 22, 2026, 4:37 AM EDT
Completed Phase 2 Interventional

MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients

NCT00078013
View directory record Official record
Conditions
Myocardial Infarction
Interventions
MCC-135
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 4:37 AM EDT
Completed No phase listed Observational Results available

Coronary Flow Reserve Following Orbital Atherectomy

NCT02339545
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary Orbital Atherectomy plus Stenting
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Chandler, Arizona • Coon Rapids, Minnesota • Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Jul 22, 2026, 4:37 AM EDT
Completed No phase listed Observational

Safe Surveillance of PCI Under Mechanical Circulatory Support With the Saranas Early Bird Bleed Monitoring System

NCT05077657
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Early Bird® Bleed Monitoring System, Impella®
Device
Lead sponsor
Saranas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Phoenix, Arizona • Tucson, Arizona • Gary, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Jul 22, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery

NCT00413244
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AndroGel 5 Grams, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Jul 22, 2026, 4:37 AM EDT